TABLE 4.
Susceptibilities of 129 selected common pathogenic yeasts to voriconazole, fluconazole, itraconazole, and amphotericin B
| Fungus (no. tested) | Antimicrobial agent | MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) |
|---|---|---|---|---|
| C. albicans (32) | Voriconazole | <0.03–4 | 0.06 | 0.5 |
| Fluconazole | 0.12–>64 | 0.5 | 32 | |
| Itraconazole | <0.03–1.0 | 0.06 | 0.5 | |
| Amphotericin B | 0.5–4 | 1.0 | 2 | |
| C. glabrata (14) | Voriconazole | 0.06–4 | 0.5 | 4 |
| Fluconazole | 4–64 | 16 | 64 | |
| Itraconazole | 0.5–>16 | 1.0 | 2 | |
| Amphotericin B | 1.0–2 | 1.0 | 2 | |
| Candida guilliermondii (8) | Voriconazole | <0.03–0.06 | 0.06 | ND |
| Fluconazole | 0.5–8 | 2 | ND | |
| Itraconazole | 0.12–0.5 | 0.25 | ND | |
| Amphotericin B | 0.5–1.0 | 1.0 | ND | |
| C. krusei (12) | Voriconazole | 0.12–0.5 | 0.25 | 0.5 |
| Fluconazole | 16–32 | 32 | 16 | |
| Itraconazole | 0.12–1.0 | 0.5 | 1.0 | |
| Amphotericin B | 0.25–1.0 | 1.0 | 1.0 | |
| C. lusitaniae (17) | Voriconazole | <0.03–0.06 | <0.03 | 0.06 |
| Fluconazole | 0.12–4 | 0.5 | 2 | |
| Itraconazole | <0.03–0.5 | 0.12 | 0.25 | |
| Amphotericin B | 0.25–2 | 1.0 | 2 | |
| C. parapsilosis (18) | Voriconazole | <0.03–0.5 | 0.06 | 0.25 |
| Fluconazole | 0.25–8 | 2 | 2 | |
| Itraconazole | 0.03–0.5 | 0.12 | 0.25 | |
| Amphotericin B | 1.0–2 | 1.0 | 1.0 | |
| C. tropicalis (16) | Voriconazole | <0.03–>16 | 0.06 | 0.25 |
| Fluconazole | 0.25–>64 | 1.0 | 32 | |
| Itraconazole | 0.06–>16 | 0.5 | 0.5 | |
| Amphotericin B | 0.5–8 | 1.0 | 1.0 | |
| Cryptococcus neoformans (12) | Voriconazole | <0.03–0.25 | 0.06 | 0.12 |
| Fluconazole | 2–16 | 4 | 16 | |
| Itraconazole | 0.06–1.0 | 0.25 | 1.0 | |
| Amphotericin B | 1.0–2 | 1.0 | 1.0 |
a
The MICs of voriconazole, fluconazole, and itraconazole correspond to prominent growth inhibition (approximately ≤50% of the growth control), and the MIC of amphotericin B corresponds to complete (100%) growth inhibition.